Asunercept companion diagnostic - Apogenix/R Biopharm

Drug Profile

Asunercept companion diagnostic - Apogenix/R Biopharm

Alternative Names: APG101 companion diagnostic; Apocept™ companion diagnostic; Asinercept companion diagnostic; CD95-Fc fusion protein companion diagnostic

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apogenix; R-Biopharm
  • Developer Apogenix
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Clinical Phase Unknown Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 09 Jun 2017 Phase-II development for Glioblastoma (Diagnosis) is ongoing in Germany (Apogenix pipeline, June 2017)
  • 07 Oct 2016 Biomarker data from a phase II trial in Glioblastoma presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 16 Feb 2016 Apogenix receives other grant from German Federal Ministry of Education and Research for Asunercept companion diagnostic development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top